You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR TRIAMCINOLONE HEXACETONIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for triamcinolone hexacetonide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00506896 ↗ Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients Completed Federal University of São Paulo Phase 2 2004-07-01 The purpose of this study is to compare the efficacy and safety of intra-articular glucocorticoid injection to its systemic use for treatment of knee synovitis in patients with Rheumatoid Arthritis
NCT00588354 ↗ Epidural Clonidine for Lumbosacral Radiculopathy Terminated National Center for Research Resources (NCRR) N/A 2006-10-01 This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.
NCT00588354 ↗ Epidural Clonidine for Lumbosacral Radiculopathy Terminated Mayo Clinic N/A 2006-10-01 This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.
NCT00660647 ↗ Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Completed Aarhus University Hospital Phase 3 2007-09-01 Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. Optimized Treatment Algorithms for Patients with Early RA
NCT00660647 ↗ Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Completed Abbott Phase 3 2007-09-01 Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. Optimized Treatment Algorithms for Patients with Early RA
NCT00660647 ↗ Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Completed Meda Pharmaceuticals Phase 3 2007-09-01 Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. Optimized Treatment Algorithms for Patients with Early RA
NCT00660647 ↗ Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Completed University of Aarhus Phase 3 2007-09-01 Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis. A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development. Optimized Treatment Algorithms for Patients with Early RA
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for triamcinolone hexacetonide

Condition Name

Condition Name for triamcinolone hexacetonide
Intervention Trials
Osteo Arthritis Knee 3
Rheumatoid Arthritis 2
Knee Osteoarthritis 2
Osteoarthritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for triamcinolone hexacetonide
Intervention Trials
Osteoarthritis 9
Osteoarthritis, Knee 5
Arthritis 4
Arthritis, Rheumatoid 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for triamcinolone hexacetonide

Trials by Country

Trials by Country for triamcinolone hexacetonide
Location Trials
United States 14
Brazil 8
Norway 3
Poland 2
Hungary 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for triamcinolone hexacetonide
Location Trials
Florida 2
Wisconsin 1
Washington 1
Minnesota 1
Virginia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for triamcinolone hexacetonide

Clinical Trial Phase

Clinical Trial Phase for triamcinolone hexacetonide
Clinical Trial Phase Trials
Phase 4 7
Phase 3 4
Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for triamcinolone hexacetonide
Clinical Trial Phase Trials
Completed 11
Unknown status 3
Not yet recruiting 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for triamcinolone hexacetonide

Sponsor Name

Sponsor Name for triamcinolone hexacetonide
Sponsor Trials
Federal University of São Paulo 5
Anika Therapeutics, Inc. 3
University of Sao Paulo General Hospital 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for triamcinolone hexacetonide
Sponsor Trials
Other 23
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.